📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 17:37
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
₹1.11 Cr Q1 Net Profit: Concord Drugs Reports 825% YoY Profit Growth Despite Equity Dilution
Concord Drugs Ltd reported a strong start to FY27, with consolidated net profit jumping to ₹1.11 Cr in Q1 (June 2026) from ₹0.12 Cr in the same quarter last year. Revenue from operations grew 54% YoY to ₹20.95 Cr, although it saw a sequential decline from the ₹37.90 Cr reported in March 2026. A key highlight is the improvement in EPS to ₹0.85 from ₹0.12 YoY, despite a 33% increase in equity share capital following a preferential allotment in March 2026. The company's quarterly profit now matches its entire FY26 annual profit of ₹1.06 Cr.
Confidence: HIGH
What changedThe company has significantly improved its bottom line YoY, with Q1 FY27 profit nearly equaling its total FY26 annual profit, despite a larger equity base.
Why it mattersFor a micro-cap company with an ₹86 Cr market cap, this level of profit growth is material and suggests a potential turnaround or scaling of operations following recent capital infusion.
Consolidated Net Profit (Q1): ₹1.11 CrYoY Profit Growth: 825%Q1 Revenue vs TTM Revenue: 26.5%Equity Capital Increase: >33%Consolidated EPS: ₹0.85
📅 Short termThe stock may react positively to the sharp YoY profit jump and the fact that earnings growth has outpaced equity dilution.
📈 Long termIf the company maintains this quarterly profit run-rate, it could lead to a significant re-rating of the stock, which currently trades at a high historical P/E.
⚠ Risk flags
- High sequential revenue volatility (44% decline from Q4 FY26)
- Micro-cap liquidity risk
- Concentrated promoter holding
Key Highlights
Consolidated Net Profit surged 825% YoY to ₹1.11 Cr from ₹0.12 Cr in June 2025
Revenue from operations increased 54% YoY to ₹20.95 Cr compared to ₹13.61 Cr in the previous year
EPS improved to ₹0.85 from ₹0.12 YoY, despite a 33% increase in equity share base
Finance costs reduced to ₹39.61 lakhs from ₹49.00 lakhs in the year-ago period
Subsidiary Proton Remedies Private Limited contributed ₹36.54 lakhs to the quarterly revenue
👀 What to Watch
Investors should monitor the sustainability of these improved margins in upcoming quarters and track the utilization of the ₹11.58 Cr raised through the recent preferential issue for growth initiatives.
Concord Drugs Q1 PAT Surges to ₹1.11 Cr; Revenue Up 56% YoY
Concord Drugs reported a strong performance for Q1 FY27, with standalone revenue reaching ₹20.90 Cr, a 56% increase from ₹13.38 Cr in the same quarter last year. Net profit saw a significant jump to ₹1.11 Cr compared to just ₹0.11 Cr in Q1 FY26. This growth is particularly notable as it outpaced a 33% equity dilution resulting from a preferential allotment of 31.75 lakh shares earlier in 2026. The company's quarterly profit now nearly matches its entire TTM PAT of ₹1.06 Cr, indicating a sharp improvement in operational efficiency.
Confidence: HIGH
What changedThe company has transitioned from a low-margin period to significant profitability growth in Q1 FY27, successfully absorbing the impact of recent equity dilution.
Why it mattersFor a micro-cap company with an ₹86 Cr market cap, generating ₹1.11 Cr in quarterly profit (vs ₹1.06 Cr for the full previous year) represents a potential structural shift in earnings power.
Q1 Standalone Revenue: ₹20.90 CrQ1 Standalone PAT: ₹1.11 CrYoY Revenue Growth: 56.1%Equity Dilution (Preferential): >33%Q1 PAT vs TTM PAT: 104.7%
📅 Short termThe stock is likely to react positively to the sharp earnings beat and the management's note on profitability outpacing dilution.
📈 Long termIf sustained, this level of profitability will significantly lower the current high P/E of 80.9, potentially leading to a valuation re-rating.
⚠ Risk flags
- Small scale of operations
- Recent equity dilution
- High P/E ratio relative to historical earnings
Key Highlights
Standalone Revenue from operations grew 56% YoY to ₹20.89 Cr.
Standalone Net Profit increased nearly 10x YoY to ₹1.11 Cr from ₹0.11 Cr.
EPS improved to ₹0.84 despite a 33% increase in equity share capital following a preferential issue.
Preferential allotment of 31,75,000 equity shares was completed at ₹36.50 per share.
Consolidated revenue includes a small contribution of ₹36.54 lakhs from subsidiary Proton Remedies Private Limited.
👀 What to Watch
Investors should monitor if the company can maintain this elevated quarterly revenue run-rate of ₹20 Cr+ and whether the improved margins are sustainable or driven by a specific product mix in the pharma segment.
